This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
by Arpita Dutt
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
What's in Store for Vertex (VRTX) this Earnings Season?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.
5 Toxic Stocks to Shun or Play Short Right Now
by Zacks Equity Research
Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.
Top Research Reports for Today: MSFT, BLK, NOC
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), BlackRock (BLK), and Northrop Grumman (NOC).
TherapeuticsMD Falls on Likely Delay in TX-004HR Approval
by Zacks Equity Research
Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback
by Arpita Dutt
Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
Vertex Pharmaceuticals (VRTX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Vertex Pharmaceuticals Incorporated (VRTX).
3 of the Best & Worst Performing Drug Stocks of Q1
by Arpita Dutt
Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.
Amgen Files for Xgeva Label Expansion, To Include Myeloma
by Zacks Equity Research
Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.
Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
by Arpita Dutt
Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.
5 Stocks that Outperformed the S&P 500 in Q1
by Zacks Equity Research
First quarter was quite impressive and we have selected five top-ranked stocks that surpassed the S&P 500 index during the period.
5 Stocks that Chaperoned Nasdaq to Double-Digit Gains in Q1
by Zacks Equity Research
The tech-heavy index, Nasdaq, outperformed and recorded a gain of 10% in the first quarter.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA
by Zacks Equity Research
AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira
Top Research Reports for Today: DIS, TXN, LMT
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Texas Instruments (TXN), and Lockheed Martin (LMT).
Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
5 Toxic Stocks to Dump or Play Short to Make Gains
by Zacks Equity Research
Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
by Arpita Dutt
Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
by Arpita Dutt
Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.
Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte
by Zacks Equity Research
Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte
5 Toxic Stocks to Abandon or Play Short Right Now
by Zacks Equity Research
In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.